People · Operator
Named in public records as an officer, director or promoter · active 2010–2024 · Pharma, Other Technology, Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Oncology Analytics, Inc. | — | Pharma | Series B | $53.5M | $850.1M | 2016 |
| SportsGrid, Inc. | — | Other Technology | Series A | $6.2M | $172.6M | 2019 |
| Ascenta Therapeutics, Inc. | — | Pharmaceuticals | Seed | $1.8M | $68.5M | 2010 |
| Alphageneron Pharmaceuticals, Inc. | — | Pharmaceuticals | Pre-Seed | $250K | $2.1M | 2023 |
| Radiance Biopharma, Inc. | — | Biotechnology | Pre-Seed | $250K | $1.5M | 2024 |
Marc Lippman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Marc Lippman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Brooks | 2 | 12 |
| Michael Powell | 1 | 14 |
| Robert Clarke | 1 | 7 |
| Thomas Hawes | 1 | 6 |
| Robert Walton | 1 | 3 |
| Ola Soderquist | 1 | 3 |
| J. Mel Sorensen | 1 | 3 |
| Andrew E. Senyei | 1 | 3 |
| Harvey Schiller | 1 | 2 |
| Joel Sussman | 1 | 2 |
| Michael J. Liang | 1 | 2 |
| John Bradburn | 1 | 2 |
| Nick Rosa | 1 | 2 |
| Louis Bock | 1 | 2 |
| Norman Selby | 1 | 2 |
| Ann J. Lamont | 1 | 2 |
| Michael Montijo | 1 | 1 |
| Marc Fishman | 1 | 1 |
| Bikash Verma | 1 | 1 |
| Graham Pockley | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.